September 25, 2016 2:00 PM ET

Pharmaceuticals

Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. MedImmune, LLC has a strategic alliance with WuXi AppTec. The company was incorporated in 1987 and is based in Gaithers...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1987

2,359 Employees

Phone:

301-398-0000

Fax:

301-527-4200

Key Executives for MedImmune, LLC

Vice President of Finance
Chief Operating Officer
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Age: 61
Executive Vice President
Compensation as of Fiscal Year 2016.

MedImmune, LLC Key Developments

Medimmune Signs Licensing Agreement with Genisphere

MedImmune, LLC has entered into a license agreement with Genisphere LLC to develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with up to six MedImmune oncology molecules, as the nanoparticle configuration may help to improve targeting of the drug. Both the companies are based in the US. Under the terms of the transaction, Genisphere will receive an upfront payment, development milestones and future royalties upon MedImmune triggering an option, and development and commercialization of therapeutics stemming from the collaboration.

Regeneron Pharmaceuticals Enters into Licensing Agreement with Medimmune

Regeneron Pharmaceuticals Inc. and MedImmune, LLC have entered into a licensing agreement under which Regeneron will use MedImmune's pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibodydrug conjugates (ADCs) as potential cancer treatments. Both the companies are based in the US. Under the terms of the agreement, Regeneron will have exclusive rights to utilize MedImmune's PBD technology to develop ADCs against a number of cancer targets. MedImmune will receive an upfront payment, development and commercial milestone payments, as well as single-digit royalties on net sales of such products. MedImmune has the option to develop and commercialize certain products created with this technology in territories outside of the US.

AstraZeneca Plc. and Medimmune Announces Update on DETERMINE

AstraZeneca plc. and MedImmune announced that DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival. In addition to investigation as monotherapy for patients with mesothelioma, tremelimumab is being studied in combination with AstraZeneca's anti-PD-L1 investigational immunotherapy durvalumab in multiple tumour types, including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers. Preclinical data have suggested that targeting both PD-L1 and CTLA-4 may have additive or synergistic effects. In the recently published Study 006, combination treatment with durvalumab and tremelimumab demonstrated antitumour activity in patients with locally advanced or metastatic NSCLC, irrespective of PD-L1 status. The company noted that it will complete a full evaluation of the final DETERMINE data, which will be submitted for presentation at an upcoming medical meeting in 2016.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MedImmune, LLC, please visit www.medimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.